wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q43140217-B4C7CA9B-EBB8-4ECD-AAE9-6E9A855E7BE9
Q43140217-B4C7CA9B-EBB8-4ECD-AAE9-6E9A855E7BE9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q43140217-B4C7CA9B-EBB8-4ECD-AAE9-6E9A855E7BE9
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.
P2860
Q43140217-B4C7CA9B-EBB8-4ECD-AAE9-6E9A855E7BE9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q43140217-B4C7CA9B-EBB8-4ECD-AAE9-6E9A855E7BE9
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
cb3fed1a19e39fcae56a8e0c1c80b6e1b7a4a586
P2860
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.